These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7554807

  • 41. Types of interpretive errors in susceptibility testing. Zone breakpoints for norfloxacin disk diffusion testing.
    Björklind A, Ringertz S, Kronvall G.
    APMIS; 1989 Oct; 97(10):941-8. PubMed ID: 2803757
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L, Maynard MJ, Morgan-Linnell SK, Horton LB, Sucgang R, Hamill RJ, Jimenez JR, Versalovic J, Steffen D, Zechiedrich L.
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [Abstract] [Full Text] [Related]

  • 44. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
    Lafredo SC, Foleno BD, Fu KP.
    Chemotherapy; 1993 Jan; 39(1):36-9. PubMed ID: 8383031
    [Abstract] [Full Text] [Related]

  • 45. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628).
    Sewell DL, Barry AL, Allen SD, Fuchs PC, Jorgensen JH, Tenover F.
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):175-9. PubMed ID: 7648838
    [Abstract] [Full Text] [Related]

  • 46. Validity of nalidixic acid screening in fluoroquinolone-resistant typhoid salmonellae.
    Butt T, Khan MY, Ahmad RN, Salman M, Afzal RK.
    J Coll Physicians Surg Pak; 2006 Jan; 16(1):31-4. PubMed ID: 16441985
    [Abstract] [Full Text] [Related]

  • 47. In vitro activity of lomefloxacin (SC 47111 or NY-198) against Chlamydia trachomatis strains.
    Segreti J, Kessler HA, Kapell K, Trenholme GM.
    Diagn Microbiol Infect Dis; 1989 Jan; 12(3 Suppl):87S-88S. PubMed ID: 2791503
    [Abstract] [Full Text] [Related]

  • 48. [In vitro evaluation of lomefloxacin].
    Dette GA, Knothe H.
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [Abstract] [Full Text] [Related]

  • 49. Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715).
    Shungu DL, Weinberg E, Gadebusch HH.
    Antimicrob Agents Chemother; 1983 Feb; 23(2):256-60. PubMed ID: 6220671
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD, Zarins LT, Ramsey MA, Bradley SF, Kauffman CA.
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.
    Biedenbach DJ, Croco MA, Barrett TJ, Jones RN.
    Eur J Clin Microbiol Infect Dis; 1999 Jun; 18(6):428-31. PubMed ID: 10442421
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Cross-resistance and cross-susceptibility between fluoroquinolone agents.
    Barry AL, Fuchs PC.
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1013-8. PubMed ID: 1666360
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.